Effects of osmotic-release methylphenidate on height and weight in children with attention-deficit hyperactivity disorder (ADHD) following up to four years of treatment

Journal of Child Neurology

Volumn 27, Issue 5, 2012, Pages 604-609

  Durá Travé, Teodoro ^a   Yoldi Petri, María Eugenia ^a   Gallinas Victoriano, Fidel ^a   Zardoya Santos, Patricia ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

ADHD; attention deficit hyperactivity disorder; body mass index; height; methylphenidate; weight

Indexed keywords

METHYLPHENIDATE;

ANTHROPOMETRIC PARAMETERS; ARTICLE; ATTENTION DEFICIT DISORDER; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ANTHROPOMETRY; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEVELOPMENTAL DISABILITIES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHYLPHENIDATE; NUTRITIONAL STATUS; RETROSPECTIVE STUDIES; SPAIN; TIME FACTORS;

EID: 84860300980     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073811422752     Document Type: Article

References (43)

1. Cardo E, Servera M, Llobera J. Estimation of the prevalence of attention deficit hyperactivity disorder among the standard population on the island of Majorca. Rev Neurol. 2007 ; 44: 10-14 (Pubitemid 350304990)
2. Froelich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007 ; 161: 857-864 (Pubitemid 47360887)
3. Merikangas KR, He JP, Brody D, Fisher PW, Bourdon K, Koretz DS. Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES. Pediatrics. 2010 ; 125: 75-81
4. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000 ; 105: 1158-1170
5. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002 ; 41 (suppl 2). S26 - S49
6. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. European Neuropsychopharmacology. 2004 ; 14: 11-28 (Pubitemid 37495027)
7. Rappley MD. Attention deficit-hyperactivity disorder. N Engl J Med. 2005 ; 352: 165-173 (Pubitemid 40096613)
8. NICE clinical guideline 72: attention-deficit/hyperactivity disorder (ADHD). London, England: NICE ; 2008:
9. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 ; 46: 894-921
10. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005 ; 44: 1015-1023
11. Brown RT, Amler RW, Freeman WS, et al. American Academy of Pediatrics, Committee on Quality Improvement, Subcommittee on Attention-Deficit/ Hyperactivity Disorder. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics. 2005 ; 115: e749 - e757
12. Molina BS, Hinshaw SP, Swanson JM, et al. MTA Cooperative Group. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009 ; 48: 484-500
13. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001 ; 108: 883-892 (Pubitemid 32947657)
14. Mulas F, Roselló B, Morant A, Hernández S, Pitarch I. The effects of psychostimulants on the cognitive results and behaviour of children with the combined subtype of attention deficit with hyperactivity. Rev Neurol. 2002 ; 35: 17-24 (Pubitemid 35447204)
15. Fernández-Jaén A, Fernández-Mayoralas D, Calleja-Pérez B, Muñoz-Jareño N. Sustained effectiveness of osmotic-release methylphenidate: a study of 266 cases. Rev Neurol. 2009 ; 48: 339-345
16. Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: A characteristic pattern. J Paediatr Child Health. 2003 ; 39: 180-185 (Pubitemid 36469915)
17. Lisska MC, Rivkees SA. Daily methylphenidate use slows the growth of children in a community sample. J Pediatr Endocrinol Metab. 2003 ; 16: 711-718 (Pubitemid 37259153)
18. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004 ; 113: 762-769
19. Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 527-537
20. Pliszka S, Matthews TL, Braslow KJ, Watson MA. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention deficit hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 520-527
21. Swanson JM, Greenhill LL, Wigal T, et al. Stimulant-related reduction of growth rates in the preschool ADHD treatment study PATS. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 1304-1313 (Pubitemid 44665447)
22. Charach A, Figueroa M, Chen S, Ickowics A, Schachar R. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 415-421 (Pubitemid 43675546)
23. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007 ; 46: 1015-1027 (Pubitemid 47224817)
24. Faraone SV, Biederman J, Morley CP, Spencer TC. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008 ; 47: 994-1009
25. Zhang H, Du M, Zhuang S. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics. 2010 ; 41: 55-59
26. Caron M. Growth in the dopamine transporter knockout animal model of ADHD. Neuropsychopharmacology. 2004 ; 29 (suppl 1). S55
27. Volkow ND, Wang GJ, Fowler JS. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 2002 ; 43: 181-187 (Pubitemid 34087672)
28. Diagnostic and Statistical Manual of Mental Disorders. 4 th ed. Washington, DC: American Psychological Association; 2000. Washington, DC: American Psychological Association ; 2000:
29. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007 ; 190: 402-409 (Pubitemid 46706952)
30. Barbudo E, Correas J, Quintero FJ Trastorno de déficit de atención e hiperactividad a lo largo de la vida. Quintero FJ, ed. Editorial. Madrid, Spain: Ergón ; 2006: 217-249.
31. The Tenth Revision of the International Classification of Diseases and Related Health Problems. Geneva, Switzerland: WHO ; 1992:
32. Swanson J, Gupta S, Williams L, Agler D, Lerner M, Wigal S. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry. 2002 ; 41: 1306-1314 (Pubitemid 38338021)
33. Greenhill LL. Diagnosing attention-deficit/hyperactivity disorder in children. J Clin Psychiatry. 1998 ; 59 (suppl 7). 31-41 (Pubitemid 28317220)
34. Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics. 2001 ; 107: e43
35. Cardo E, Severa-Barceló M. The prevalence of attention deficit hyperactivity disorder. Rev Neurol. 2005 ; 40 (suppl 1). S11 - S15
36. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003 ; 112: e404 - e413
37. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 2006 ; 160: 82-90 (Pubitemid 43042140)
38. Holtkamp K, Konrad K, Muller B, et al. Overweight and obesity in children with attention deficit/hyperactivity disorder. Int J Obes Relat Metab Disord. 2004 ; 28: 685-689 (Pubitemid 38580977)
39. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005 ; 90: 801-806 (Pubitemid 41081356)
40. Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr. 2010 ; 157: 635-640
41. Kramer JR, Loney J, Ponto LB, Roberts MA, Grossman S. Predictors of adult height and weight in boys treated with methylphenidate for childhood behaviour problems. J Am Acad Child Adolesc Psychiatry. 2000 ; 39: 517-524 (Pubitemid 30185548)
42. Dubnov-Raz G, Perry A, Berger I. Body mass index of children with attention-deficit/hyperactivity disorder. J Child Neurol. 2011 ; 26: 302-308
43. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004 ; 43: 559-567 (Pubitemid 38812367)